Jon Saxe - SciClone Pharmaceuticals Insider

SciClone Pharmaceuticals Inc -- USA Stock  

USD 11.10  0.050000  0.45%

Independent Chairman of the Board

Mr. Jon S. Saxe J.D., is an Independent Chairman of the Board of SciClone Pharmaceuticals, Inc., since July 29, 2009. He has served as the Chairman of our Board of Directors since July 2009 and as a Director since August 2000. Mr. Saxe was President of PDL BioPharma, Inc. from 1995 to early 1999. From 1993 to 1995, Mr. Saxe was President of Saxe Associates, Inc., consultants to VC firms and biotechnology, diagnostic, and pharmaceutical companies. He was the President and CEO of Synergen, Inc., a biotechnology company acquired by Amgen, from 1989 to 1993. Mr. Saxe is former Vice President, Licensing and Corporationrationrate Development and Head of Patent Law for HoffmannLaRoche Inc., where he worked for almost 30 years
Age: 78  Chairman Since 2009      
650-358-3456  www.sciclone.com
Saxe received his B.S. Ch.E. from CarnegieMellon University, his J.D. from George Washington University School of Law and his LL.M. from New York University School of Law. He serves as a director of other public and private companies, including Durect Corporationrationrationration and as Chairman of VistaGen Therapeutics, Inc.

Jon Saxe Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.28 % which means that it generated profit of $11.28 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 19.56 % meaning that it created $19.56 on every $100 dollars invested by stockholders.

Similar Executives

Found 7 records

CHAIRMAN Since

Norman SchwartzBio Rad Laboratories Inc
2012
Roger KimmelEndo International plc
2007
Jeffrey LeidenVertex Pharmaceuticals Incorpor
2012
Paul BisaroAllergan plc
2016
Miles WhiteAbbott Laboratories
1999
Dennis GillingsQuintiles IMS Holdings Inc
2015
Joshua BogerVertex Pharmaceuticals Incorpor
2009

Entity Summary

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals Inc (SCLN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 590 people. SciClone Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Fundamentals Comparison Now
   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
Hide  View All  Next  Launch Fundamentals Comparison
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add SciClone Pharmaceuticals Inc to your portfolio

Top Management

SciClone Pharmaceuticals Leadership Team
Charles Meng, VP
Richard Hawkins, Director
Gregg Lapointe, Director, MBA
Hong Zhao, CEO
Wilson Cheung, CFO
Nancy Chang, Director, Ph.D
Anthony Lapointe, Director, MBA
Lan Xie, CFO, MBA
Raymond Low, President, MBA
Robert King, President, Ph.D
Simon Li, Director, MBA
Jon Saxe, Chairman
Friedhelm Blobel, CEO, Ph.D

Stock Performance

SciClone Pharmaceuticals Performance Indicators